Centene Corp (CNC) carries a ŷRobot AI score of 63 out of 100. The model's fair value estimate is $73.54, 4.3% above the last close of $70.51. The chart signal reads Sell.
| Metric | CNC |
|---|---|
| AI score | 63 / 100 |
| Chart signal | Sell |
| Fair value estimate | $73.54 |
| Upside to fair value | 4.3% |
| Previous close | $70.51 |
| P/E | -5.89 |
| Price / sales | 0.17 |
| Market cap | $34.66B |
| EPS | -10.36 |
| Revenue growth | 9.7% |
| 1-year price change | 1.4% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
As of Oct 15, 2026, ŷRobot's fair-value model estimates Centene Corp (CNC) at $73.54 against a last close of $70.51, implying 4.3% upside to the model's estimate.
The chart-signal model classifies CNC as Neutral as of Oct 15, 2026, with a signal score of -0.09 on a -1 to 1 scale.
CNC scores 63 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 15, 2026.
CNC trades at -5.9 times earnings and 0.2 times sales as of Oct 15, 2026.
ŷRobot's seasonal forecast curve for CNC reads +0.8% at 30 days, +3.1% at 90 days, and +1.4% at one year as of Oct 15, 2026. Seasonal tendencies are historical patterns, not predictions.
Centene Corp's revenue growth is +9.7% and free-cash-flow growth is +81.6% on the latest reported figures.
CNC chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.